Long Term, Single-arm, Open-label Extension Study of Protocol AC-055-305 to Assess the Safety, Tolerability and Efficacy of Macitentan in Subjects With Eisenmenger Syndrome
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 05 Oct 2017
At a glance
- Drugs Macitentan (Primary)
- Indications Eisenmenger complex
- Focus Adverse reactions
- Acronyms MAESTRO-OL
- Sponsors Actelion Pharmaceuticals
- 05 Sep 2017 Planned End Date changed from 30 Aug 2018 to 30 Nov 2017.
- 05 Sep 2017 Planned primary completion date changed from 31 Jul 2018 to 30 Nov 2017.
- 03 Jul 2017 Planned End Date changed from 1 Sep 2020 to 30 Aug 2018.